Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)

Table 3

Changes in biochemical measurements.

Parameters	Group	0 month	12 months	P-value	Difference	P-value
Aspartate aminotransferase (IU/L)	T	30.6±13.9	35.3±19.0	0.583	4.8±17.6
	L	32.0±10.3	32.3±12.3	>0.999	0.3±5.6	0.672
Alanine aminotransferase (IU/L)	T	39.8±26.6	50.3±32.3	0.261	10.5±28.3
	L	43.7±26.2	46.4±28.7	0.344	2.7±8.6	0.672
γ Glutamyl transpeptidase (IU/L)	T	58.9±43.0	69.2±72.7	0.683	10.3±56.8
	L	60.9±63.8	57.6±57.8	0.463	−3.3±9.2	0.471
Total cholesterol (mg/dL)	T	217.8±42.3	212.4±29.7	0.505	−5.3±19.8
	L	201.0±38.9	198.9±31.8	0.345	−2.1±23.8	0.525
Triglyceride (mg/dL)	T	122.3±54.3	128.5±55.1	0.433	6.2±54.3
	L	120.9±45.7	122.0±50.9	0.866	1.1±31.8	0.899
HDL cholesterol (mg/dL)	T	52.8±13.1	51.1±12.9	0.283	−1.8±4.8
	L	46.7±9.2	45.7±11.0	0.343	−1.0±3.1	>0.999
Free fatty acids (mEq/L)	T	0.87±0.26	0.59±0.22	0.005	−0.28±0.27
	L	0.50±0.26	0.66±0.22	0.237	0.16±0.29	0.007
Fasting plasma glucose (mg/dL)	T	116.5±20.3	112.3±11.1	0.247	−4.2±15.5
	L	122.8±20.2	137.0±28.6	0.078	14.2±12.9	0.031
IRI (μU/mL)	T	12.5±6.1	14.5±11.1	0.720	2.1±7.5
	L	12.6±6.4	10.2±3.8	0.498	−2.4±4.8	0.396
Hemoglobin A1c (%)	T	6.4±0.6	6.4±0.4	0.552	0.0±0.4
	L	6.7±1.0	7.2±1.2	0.017	0.5±0.2	0.001
HOMA-IR	T	3.55±1.68	3.98±2.92	>0.999	0.43±2.45
	L	3.84±2.30	3.43±1.46	0.686	−0.41±1.63	0.770
HOMA-β	T	98.1±71.2	115.5±103.6	0.374	17.4±42.8
	L	84.5±53.6	58.5±33.6	0.043	−26.0±29.6	0.062
Creatinine (mg/dL)	T	0.8±0.2	0.9±0.2	0.149	0.03±0.06
	L	0.8±0.3	0.8±0.3	0.655	0.00±0.06	0.274
Uric acid (mg/dL)	T	5.8±1.4	6.3±1.2	0.016	0.4±0.5
	L	5.7±1.5	5.2±1.3	0.046	−0.5±0.5	0.002
Primary bile acids (μmol/L)	T	1.3±1.7	2.0±2.3	0.534	0.7±3.0
	L	3.0±3.2	2.8±2.6	0.345	−0.2±1.6	0.447
Secondary bile acids (μmol/L)	T	1.2±1.0	1.4±1.8	0.906	0.2±1.3
	L	2.4±3.4	2.4±2.5	0.735	0.0±2.1	0.554
Microalbumin in urine (μg/mL)	T	23.9±43.9	24.5±46.6	0.173	−0.5±53.0
	L	76.1±113.7	39.5±46.2	0.173	−36.6±58.5	0.884

Data are presented as mean ± SD. Parameters at 0 and 12 months of treatment were compared by Wilcoxon's matched-pair signed-rank test. Differences are shown as [value at 12 months − value at 0 month]. Differences between groups (telmisartan (T) versus losartan (L)) were compared by Mann-Whitney 𝑈 test.
HDL: high-density lipoprotein, IRI: immunoreactive insulin, and HOMA-IR: homeostasis model assessment-insulin resistance.